Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

PRESS: Doubts Raised Over AstraZeneca-Oxford Vaccine Data - FT

Thu, 26th Nov 2020 06:55

(Alliance News) - Concerns are increasing over the way Oxford University and AstraZeneca PLC have handled the early readout from trials of their coronavirus vaccine candidate, the Financial Times reported on Wednesday.

https://www.ft.com/content/4583fbf8-b47c-4e78-8253-22efcfa4903a

The results were hailed a success for showing an average efficacy of 70%, a figure reached by pooling the results from cohorts on two different dosing regimens.

AstraZeneca on Monday said one dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart. Another dosing regimen showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.

But on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the US government's funding programme for vaccine development, disclosed that the subgroup that scored 90% was limited to people aged 55 or below, a demographic with lower risk of developing severe Covid-19, FT reported.

Oxford and AstraZeneca did not disclose the age breakdown on Monday, when results were released.

AstraZeneca shares closed 2.4% lower on Wednesday in London at 7,810.00 pence each. The stock is down 6.0% so far this week.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
6 Jul 2025 12:41

Sunday newspaper round-up: Trade, AstraZeneca, Tax hikes

(Sharecast News) - Brussels is heading into a critical week, with just two to go to clinch a trade agreement with the US or face a 50% levy on its exp...

4 Jul 2025 17:48

London close: FTSE finishes flat ahead of Trump tariff deadline

(Sharecast News) - London stocks ended Thursday little changed at the top tier but weaker further down the board, as investors weighed fresh economic ...

4 Jul 2025 17:19

CORRECT: AstraZeneca bladder cancer treatment secures EU approval

(Correcting name of trial, primary endpoint and Dave Fredrickson's title.)

4 Jul 2025 16:58

LONDON MARKET CLOSE: Stocks fade as tariff deadline looms large

(Alliance News) - London's FTSE 100 ended flat as tariff worries kept enthusiasm to a minimum on Friday, while the pound edged slightly lower after a ...

4 Jul 2025 11:58

LONDON MARKET MIDDAY: Europe down ahead of US tariff decision deadline

(Alliance News) - London's blue chip index remained lower at midday on Friday, as investors weigh China's decision to slap levies on major European br...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.